Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
19 Oct 2009 10:31 AM
RNS
'Best Technology 2009' Award
09 Oct 2009 10:14 AM
RNS
Appointment of Joint Broker
29 Sep 2009 07:00 AM
RNS
Interim Results
21 Sep 2009 09:55 AM
RNS
8th Annual Bio Investor Forum
17 Sep 2009 07:00 AM
RNS
JMP Healthcare Focus Conferen
24 Jul 2009 12:12 PM
RNS
Result of AGM
23 Jul 2009 04:17 PM
RNS
Directors' Dealings
30 Jun 2009 07:00 AM
RNS
Annual Report and Accounts
24 Jun 2009 07:00 AM
RNS
Preliminary Results
17 Jun 2009 07:00 AM
RNS
Piper Jaffray Europe Conferen
23 Mar 2009 07:00 AM
RNS
Directors' Dealings
04 Feb 2009 12:32 PM
RNS
Share Options
02 Feb 2009 02:33 PM
RNS
Cephalon license exercise
30 Jan 2009 07:00 AM
RNS
Successful trial results
22 Dec 2008 12:00 PM
RNS
further instalment of grant
25 Nov 2008 07:00 AM
RNS
Option Agreement with Cephalo
12 Nov 2008 07:00 AM
RNS
Grant Award
21 Oct 2008 09:31 AM
RNS
Patents Granted
17 Oct 2008 04:22 PM
RNS
Additional Listing and Total
25 Sep 2008 07:00 AM
RNS
Interim Results
05 Aug 2008 03:44 PM
RNS
AGM Result
10 Jul 2008 07:00 AM
RNS
Second Placing
02 Jul 2008 07:30 AM
RNS
Toxicology study
02 Jul 2008 07:00 AM
RNS
Fund Raising
30 Jun 2008 03:00 PM
RNS
Annual Report and Accounts
20 May 2008 07:00 AM
RNS
Pre-clinical Data
13 May 2008 06:00 AM
RNS
Trademark Approval
08 May 2008 07:00 AM
RNS
Preliminary Results
26 Feb 2008 07:00 AM
RNS
Phase IIb Trial of IPP-201101
08 Jan 2008 07:00 AM
RNS
Novel Drug Candidate
18 Dec 2007 12:51 PM
RNS
Directors' Dealings
06 Dec 2007 07:01 AM
RNS
Initiation of Phase IIb trial
16 Nov 2007 12:28 PM
RNS
Appointment of Nomad
28 Sep 2007 07:02 AM
RNS
Interim Results
22 Aug 2007 07:00 AM
RNS
Compound Discovery
20 Aug 2007 10:17 AM
RNS
AIM Rule 26
13 Aug 2007 04:17 PM
RNS
Directors' Dealing
06 Aug 2007 02:40 PM
RNS
Grant of Options
10 Jul 2007 07:01 AM
RNS
Pivotal phase II/III trial
13 Jun 2007 02:00 PM
RNS
AGM and Board Update
01 May 2007 07:01 AM
RNS
Preliminary Results
27 Apr 2007 03:57 PM
RNS
Board Appointment
15 Feb 2007 07:00 AM
RNS
Appointment of adviser
07 Feb 2007 07:00 AM
RNS
Board Changes
19 Jan 2007 08:57 AM
RNS
Total Voting Rights
05 Jan 2007 02:27 PM
RNS
Issue of Equity
27 Dec 2006 02:53 PM
RNS
Total Voting Rights
21 Dec 2006 07:00 AM
RNS
Issue of Equity
30 Oct 2006 07:00 AM
RNS
Further Phase II Data
17 Oct 2006 07:00 AM
RNS
Phase II Data

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100

Latest directors dealings